英国COVID-19候选疫苗ChAdOx1:将于下个月开始临床试验

2020-03-21 Allan MedSci原创

英国公共卫生(PHE)部门研究人员正在对COVID-19候选疫苗ChAdOx进行临床前测试。

英国公共卫生(PHE)部门研究人员正在对COVID-19候选疫苗ChAdOx进行临床前测试。PHE的国家感染服务研究负责人Miles Carroll说:“如果进展顺利,可能在下个月左右进行人体安全性试验”。

ChAdOx1是由牛津大学开发的,包含COVID-19病毒表面突触蛋白(Spike)的遗传序列,是全球正在研发的针对COVID-19的几种疫苗之一。牛津大学Jenner研究所所长Adrian Hill说:“面对日益严重的疫情,对疫苗的需求是迫切的,但是我们的研究人员仍会遵循所有标准的试验安全性要求,对COVID-19候选疫苗ChAdOx1进行临床前及临床测试”。

PHE将在两种动物模型中进行临床前研究,在接受可控剂量的新型冠状病毒之前,对动物模型进行免疫接种,这可能为下个月ChAdOx1的人体安全性试验铺平道路。

 

原始出处:

https://www.firstwordpharma.com/node/1709585

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1937285, encodeId=2a40193e28578, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Wed Mar 03 11:44:27 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782933, encodeId=04b91e82933a2, content=<a href='/topic/show?id=b78845e0ba' target=_blank style='color:#2F92EE;'>#ChAdOx1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4570, encryptionId=b78845e0ba, topicName=ChAdOx1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Feb 14 06:44:27 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562040, encodeId=011915620409f, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5133, encryptionId=6875513376, topicName=COVID-19候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=077d15252580, createdName=piaojinhua, createdTime=Mon Mar 23 09:44:27 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380851, encodeId=01af38085132, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Sun Mar 22 22:54:54 CST 2020, time=2020-03-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1937285, encodeId=2a40193e28578, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Wed Mar 03 11:44:27 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782933, encodeId=04b91e82933a2, content=<a href='/topic/show?id=b78845e0ba' target=_blank style='color:#2F92EE;'>#ChAdOx1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4570, encryptionId=b78845e0ba, topicName=ChAdOx1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Feb 14 06:44:27 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562040, encodeId=011915620409f, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5133, encryptionId=6875513376, topicName=COVID-19候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=077d15252580, createdName=piaojinhua, createdTime=Mon Mar 23 09:44:27 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380851, encodeId=01af38085132, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Sun Mar 22 22:54:54 CST 2020, time=2020-03-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1937285, encodeId=2a40193e28578, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Wed Mar 03 11:44:27 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782933, encodeId=04b91e82933a2, content=<a href='/topic/show?id=b78845e0ba' target=_blank style='color:#2F92EE;'>#ChAdOx1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4570, encryptionId=b78845e0ba, topicName=ChAdOx1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Feb 14 06:44:27 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562040, encodeId=011915620409f, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5133, encryptionId=6875513376, topicName=COVID-19候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=077d15252580, createdName=piaojinhua, createdTime=Mon Mar 23 09:44:27 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380851, encodeId=01af38085132, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Sun Mar 22 22:54:54 CST 2020, time=2020-03-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1937285, encodeId=2a40193e28578, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27468, encryptionId=d6262e4688b, topicName=候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Wed Mar 03 11:44:27 CST 2021, time=2021-03-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1782933, encodeId=04b91e82933a2, content=<a href='/topic/show?id=b78845e0ba' target=_blank style='color:#2F92EE;'>#ChAdOx1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4570, encryptionId=b78845e0ba, topicName=ChAdOx1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sun Feb 14 06:44:27 CST 2021, time=2021-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562040, encodeId=011915620409f, content=<a href='/topic/show?id=6875513376' target=_blank style='color:#2F92EE;'>#COVID-19候选疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5133, encryptionId=6875513376, topicName=COVID-19候选疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=077d15252580, createdName=piaojinhua, createdTime=Mon Mar 23 09:44:27 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380851, encodeId=01af38085132, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Sun Mar 22 22:54:54 CST 2020, time=2020-03-22, status=1, ipAttribution=)]
    2020-03-22 wxl882001

    了解一下

    0

相关资讯

英国首位患者在NHS内接受诺华的Luxturna基因疗法治疗先天性黑蒙病

英国国家医疗服务体系(NHS)表示,作为其长期计划的一部分,诺华公司的Luxturna(voretigene neparvovec)基因疗法将用于首位遗传性视网膜疾病-莱伯先天性黑蒙病(LCA)患者以恢复视力。

英国确认首例新型冠状病毒感染病例引起全球关注

在世界卫生组织(WHO)前天宣布爆发全球紧急事件之后,英国昨天早上确认了头两例新型冠状病毒感染病例。

新加坡:批评英国、瑞士消极抗疫:他们都放弃了

新冠疫情暴发后,英国抛出所谓“群体免疫”的抗疫策略,令全世界跌破眼镜。民众、媒体乃至学者都对其反应强烈。对此,新加坡跨部门抗疫工作小组负责人、国家发展部长兼财政部第二部长黄循财

英国授权开展全球针对肾脏移植免疫排斥反应的CAR-Treg细胞疗法临床研究

英国药品保健产品监管局(MHRA)已授权Sangamo Therapeutics开展首个嵌合抗原受体调节性T细胞(CAR-Treg)疗法TX200的临床试验STEADFAST。TX200正在研究用于预防HLA-A2错配肾脏移植治疗终末期肾脏疾病(ESRD)后免疫介导的排斥反应。

英国将领导价值2亿英镑的50万人的全基因组测序

英国研究与创新中心宣布了一项新的价值2亿英镑项目,对50万人的遗传密码进行测序,以更好地理解,诊断,治疗和预防改变生命的疾病,包括癌症和痴呆症。

英国新增4例新型冠状病毒感染病例,目前感染总计8人

英国新增四例新型冠状病毒(2019-nCoV)感染病例,内政大臣普里蒂·帕特尔(Priti Patel)宣布疫情是"对公共健康的严重且迫在眉睫的威胁",目前英国感染人数总计8人。

拓展阅读

磺脲类药物可减少新冠病毒引起的神经炎症和血脑屏障损伤!

格列本脲可能通过抑制NLRP3炎症小体的激活和促炎细胞因子的释放来介导其抗炎作用,从而减轻Covid-19诱导的神经炎症。

JAMA:即使轻微的COVID-19,也会对大脑造成明显的伤害!

即使轻微的COVID-19,也会对大脑造成明显的伤害!

European Radiology:人工智能,实现COVID-19的“一站式”诊断及检测

现阶段,胸部CT扫描已成为诊断COVID-19的一项重要手段,但由于COVID-19的某些CT特征与其他病毒性感染相似,因此诊断准确性有待商榷。

Lancet:震惊——COVID-19导致的死亡人数我们看到的可能只是冰山一角!

这场大流行的全面影响远远大于仅由COVID-19引起的死亡报告所显示的情况。

Nature:新冠病毒损伤大脑

该研究揭示了一种空间模式:形成主要嗅觉网络的边缘脑区在感染COVID-19后出现异常变化。

Kidney Int:淋巴细胞分析谱可帮助区分实体器官移植后COVID-19的轻重度风险

SOT受者的CD3和CD8淋巴减少与严重COVID-19感染高度相关。